|
US6262119B1
|
|
Methods of treating immunopathologies using polyunsaturated fatty acids
|
|
US5959087A
|
|
Tumour necrosis factor binding ligands
|
|
AUPO434796A0
|
|
Novel peptides
|
|
AUPO410796A0
|
|
Method of treating benign prostatic hyperplasia
|
|
AUPO383096A0
|
|
Novel peptides
|
|
AUPO330996A0
|
|
Novel peptides
|
|
AUPO216596A0
|
|
Novel peptides
|
|
AUPO203596A0
|
|
Hormone therapy
|
|
AUPO061096A0
|
|
Novel peptides
|
|
AUPN953896A0
|
|
Treatment of t-cell mediated diseases
|
|
AUPN925096A0
|
|
Methods of treatment
|
|
AU3765895A
|
|
Synthetic polyunsaturated fatty acid analogues
|
|
CA2203791A1
|
|
Synthetic polyunsaturated fatty acid analogues
|
|
AU3645195A
|
|
Modified polyunsaturated fatty acids
|
|
AUPN576795A0
|
|
Anti-viral therapy
|
|
AUPN366795A0
|
|
Formulation for preventing reproductive function
|
|
AUPN329995A0
|
|
Method of preventing intestinal disorders by inhibiting release of bile
|
|
AUPN326995A0
|
|
Method for improved treatment of intestinal disorders
|
|
AUPN150695A0
|
|
Compound for the treatment of epilepsy
|
|
US5644034A
|
|
Tumour necrosis factor binding ligands
|
